1. 101P Results of the NLG2105 phase I trial using the IDO pathway inhibitor indoximod, in combination with radiation and chemotherapy, for children with newly diagnosed DIPG. (15th December 2019) Authors: Johnson, T S; Aguilera, D; Al-Basheer, A; Berrong, Z; Castellino, R C; Eaton, B R; Esiashvili, N; Foreman, N; Heger, I M; Kennedy, E P; Vahanian, N; Martin, W; Pacholczyk, R; Ring, E; Sadek, R F; Smith, A; Shimoda, M; Macdonald, T J; Munn, D H Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗